BiotechTube

Treatment for Fibromyalgia

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia

Trial Timeline

Jun 1, 2008 → Apr 1, 2011

NCT ID
NCT00725101

About Treatment for Fibromyalgia

Treatment for Fibromyalgia is a pre-clinical stage product being developed by Eli Lilly for Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00725101. Target conditions include Fibromyalgia.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00725101Pre-clinicalCompleted

Competing Products

20 competing products in Fibromyalgia

See all competitors
ProductCompanyStageHype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
DS-5565 + PlaceboDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
ASP8062 + PlaceboAstellas PharmaPhase 2
52
ASP0819 + PlaceboAstellas PharmaPhase 2
52
DuloxetineShionogiPhase 3
77
Duloxetine 60 mg + PlaceboShionogiPhase 3
77
zonisamideEisaiApproved
85
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
DuloxetineEli LillyApproved
85
duloxetine hydrochloride + placeboEli LillyApproved
85
duloxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyApproved
85
Duloxetine + PlaceboEli LillyPhase 3
77
duloxetine + placeboEli LillyPhase 3
77
Eszopiclone + placeboSumitomo PharmaApproved
85

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85